ClinicalTrials.gg
CompletedNCT00549302Updated Apr 9, 2013Results posted

Study the Safety and Effectiveness of Tadalafil on High Blood Pressure in the Blood Vessel Going From the Heart to the Lungs

A Phase 3 interventional study of tadalafil and tadalafil in Hypertension, Pulmonary, sponsored by Eli Lilly and Company. Completed at 10 sites in 10 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2013-04-09.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
357
Allocation
Non-randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies testing tadalafil in Hypertension, Pulmonary — 3 open to participants now, 3 under way, 2 of them phase 3. Tadalafil · Hypertension, Pulmonary.

Enrollment
3rd of 18
357 · median 40
Started
2005
with 1 other
Phase 3
8 of 18
2 open now
Registered
2nd of 18
by date
Lead sponsor
3 of 18
Eli Lilly and Company

Among the 18 studies testing tadalafil in Hypertension, Pulmonary, this one is the 3rd largest by enrollment, is one of 2 that started in 2005, is one of 8 in phase 3, and was the 2nd registered.

Hypertension, Pulmonary

1,092 studies on the registry are indexed under Hypertension, Pulmonary; 243 are open to participants now.

Browse Hypertension, Pulmonary studies →

Open to participants now

3 of the 18 studies testing tadalafil in Hypertension, Pulmonary are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About tadalafil

Tadalafil: first FDA approval 2003 (CIALIS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 163 Hypertension, Pulmonary studies recruiting now, 99 (61%) set no upper age limit and 26 (16%) stop at 75 or younger; 39 take children under 18; 24 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing tadalafil in Hypertension, Pulmonary, or all of them as a file.
02

Study summary

Study to determine the long term safety of tadalafil in patients with increased blood pressure in the blood vessel that carries blood from the right heart to the lungs and to see if it will keep the disease from getting worse.

03

Conditions studied

  • Hypertension, Pulmonary
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have participated and discontinued in the previous PAH placebo controlled study due to clinical worsening on placebo or tadalafil 2.5 mg, 10mg, or 20 mg
  • Must have completed Week 16 of the previous PAH study and had either no clinical worsening or became clinically worse at the Week 16 visit on placebo or tadalafil 2.5 mg, 10mg, or 20 mg
  • Females who have a negative urine pregnancy test and are willing to use 2 types of
  • Be 12 years or older (country specific regulations apply) with parental approval

Exclusion criteria

Exclusion Criteria:

  • Participated in the placebo controlled study and had clinical worsening on 40 mg tadalafil
  • Have left-sided heart disease
  • Have a musculoskeletal disorder that limits being able to get around
  • Nitrate use
  • Certain current systemic treatments
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
357 participants (actual)

Study arms

  • Active comparator
    20 mg tadalafil

    20 milligram (mg) tadalafil taken once a day

    Drug: tadalafil

  • Active comparator
    40 mg tadalafil

    40 mg tadalafil tablet taken once a day

    Drug: tadalafil

Interventions

  • 20 milligram (mg) tablet, taken by mouth once a day for 52 weeks for the phase 1 portion. Open label phase includes 40 mg tablet taken by mouth once a day until the sponsor concludes the study or tadalafil becomes commercially available for the treatment of Pulmonary Arterial Hypertension (PAH).

    Also known as: LY450190, Cialis, IC351

  • 40 mg tablet taken by mouth once a day for 52 weeks in phase 1. Open label phase includes 40 mg tablet taken by mouth once a day until the sponsor concludes the study or tadalafil becomes commercially available for the treatment of PAH.

    Also known as: LY450190, Cialis, IC351

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs)

    A summary of serious and all other non-serious AEs, which include adverse events reported for laboratory tests and vital signs, is located in the Reported Adverse Event module.

    Time frame: Baseline (Double-Blind Period) up to Week 243 (End of Open-Label Period)

Secondary outcomes

  1. 6-Minute Walk Distance (6MWD) at Baseline and Weeks 16, 28, 40 and 52

    6MWD measured the distance a participant was able to walk unassisted in 6 minutes.

    Time frame: Baseline and Weeks 16, 28, 40 and 52

  2. Borg Dyspnea Assessment at Baseline and Weeks 16, 28, 40 and 52

    Borg dyspnea score is a participant rated measure of their greatest degree of shortness of breath during exertion (6-minute walk test). Score ranged from 0 (nothing at all) to 10 (very, very severe \[maximal\]).

    Time frame: Baseline and Weeks 16, 28, 40 and 52

  3. Probability of No Pulmonary Arterial Hypertension (PAH) Deterioration at Weeks 16, 28, 40 and up to 52

    World Health Organization Functional Classification Assessment (WHO FC) is a method of classifying disease severity in PAH. The classes are: Class I: pulmonary hypertension (PH) but without resulting limitation of physical activity, Class II: PH resulting in slight limitation of physical activity, Class III: PH resulting in marked limitation of physical activity, Class IV: PH with inability to carry out any physical activity without symptoms. Deterioration of WHO FC is defined as moving to a higher WHO FC within one visit. Results are presented as Kaplan-Meier estimates (% probability) of remaining free from WHO FC deterioration after a given time.

    Time frame: Baseline and Weeks 16, 28, 40 and 52

07

Results

Posted Feb 18, 2013

Participant flow

Double-Blind
Participant flow — Double-Blind
MilestoneTadalafil 20 mg Double BlindTadalafil 40 mg Double-BlindTadalafil 40 mg Open-Label
Started632940
Received at least one dose of study drug632940
Completed522410
Not completed11530
Withdrew: Death290
Withdrew: Adverse event3160
Withdrew: Withdrawal by subject380
Withdrew: Investigator decision150
Withdrew: Sponsor decision010
Withdrew: Lost to follow-up120
Withdrew: New drug pulmonary atrial hypertension1100
Withdrew: New condition or starts new therapy020
Open-Label
Participant flow — Open-Label
MilestoneTadalafil 20 mg Double BlindTadalafil 40 mg Double-BlindTadalafil 40 mg Open-Label
Started00286
Completed00217
Not completed0069
Withdrew: Adverse event0011
Withdrew: Death0040
Withdrew: Investigator decision005
Withdrew: Lost to follow-up002
Withdrew: Other003
Withdrew: New drug pulmonary atrial hypertension002
Withdrew: Withdrawal by subject006

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs)

A summary of serious and all other non-serious AEs, which include adverse events reported for laboratory tests and vital signs, is located in the Reported Adverse Event module.

Time frame:
Baseline (Double-Blind Period) up to Week 243 (End of Open-Label Period)
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs)
participantsTadalafil 20 mg or 40 mg Double-Blind and 40 mg Open-Label
Serious AEs184
Other Non-Serious AEs334
Secondary6-Minute Walk Distance (6MWD) at Baseline and Weeks 16, 28, 40 and 52

6MWD measured the distance a participant was able to walk unassisted in 6 minutes.

Time frame:
Baseline and Weeks 16, 28, 40 and 52
Reported as:
Mean · meters (m)
6-Minute Walk Distance (6MWD) at Baseline and Weeks 16, 28, 40 and 52
meters (m)Tadalafil 20 Milligrams (mg) Double-BlindTadalafil 40 mg Double-Blind
Distance walked at Baseline (n=63, 287397.74 ± 71.74375.38 ± 93.41
Distance walked at Week 16 (n=58, 272)396.37 ± 77.01381.47 ± 96.86
Distance walked at Week 28 (n=55, 250)406.41 ± 106.76384.97 ± 95.03
Distance walked at Week 40 (n=51, 241)411.81 ± 78.72386.57 ± 94.04
Distance walked at Week 52 (n=51, 235)415.31 ± 79.82394.00 ± 91.56
Endpoint-Week 52 or LOCF (n=60,281)401.52 ± 90.29379.80 ± 99.12
SecondaryBorg Dyspnea Assessment at Baseline and Weeks 16, 28, 40 and 52

Borg dyspnea score is a participant rated measure of their greatest degree of shortness of breath during exertion (6-minute walk test). Score ranged from 0 (nothing at all) to 10 (very, very severe \[maximal\]).

Time frame:
Baseline and Weeks 16, 28, 40 and 52
Reported as:
Mean · units on a scale
Borg Dyspnea Assessment at Baseline and Weeks 16, 28, 40 and 52
units on a scaleTadalalfil 20 Milligrams (mg)Tadalafil 40 mg
Score at Baseline (n=62, 287)3.41 ± 2.383.65 ± 2.43
Score at Week 16 (n=58, 271)3.41 ± 2.483.51 ± 2.35
Score at Week 28 (n=54,249)3.46 ± 2.403.44 ± 2.21
Score at Week 40 (n=51, 240)3.21 ± 2.433.38 ± 2.27
Score at Week 52 (n=51,235)3.68 ± 2.433.29 ± 2.16
Endpoint-Week 52 or LOCF (n=60,281)3.75 ± 2.343.54 ± 2.36
SecondaryProbability of No Pulmonary Arterial Hypertension (PAH) Deterioration at Weeks 16, 28, 40 and up to 52

World Health Organization Functional Classification Assessment (WHO FC) is a method of classifying disease severity in PAH. The classes are: Class I: pulmonary hypertension (PH) but without resulting limitation of physical activity, Class II: PH resulting in slight limitation of physical activity, Class III: PH resulting in marked limitation of physical activity, Class IV: PH with inability to carry out any physical activity without symptoms. Deterioration of WHO FC is defined as moving to a higher WHO FC within one visit. Results are presented as Kaplan-Meier estimates (% probability) of remaining free from WHO FC deterioration after a given time.

Time frame:
Baseline and Weeks 16, 28, 40 and 52
Reported as:
Number · probability (%) no PAH deterioration
Probability of No Pulmonary Arterial Hypertension (PAH) Deterioration at Weeks 16, 28, 40 and up to 52
probability (%) no PAH deteriorationTadalafil 20 Milligrams (mg) Double-BlindTadalafil 40 mg Double-Blind
Week 16 (n=57, 262)95 (85 to 98)96 (93 to 98)
Week 28 (n=50, 238)88 (77 to 94)90 (86 to 93)
Week 40 (n=45, 222)81 (68 to 89)88 (83 to 91)
Week 52 (n=33,136)81 (68 to 89)85 (80 to 89)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tadalafil 20 mg or 40 mg Double-Blind and 40 mg Open-Label—184/357 (51.5%)334/357 (93.6%)
Most frequent serious events
Showing 10 of 241
Most frequent serious events
EventTadalafil 20 mg or 40 mg Double-Blind and 40 mg Open-Label
Right ventricular failureCardiac disorders28/357
Pulmonary arterial hypertensionRespiratory, thoracic and mediastinal disorders26/357
PneumoniaInfections and infestations16/357
Cardiac failure congestiveCardiac disorders10/357
SyncopeNervous system disorders10/357
Cardiac failureCardiac disorders9/357
Gastrointestinal haemorrhageGastrointestinal disorders8/357
AnaemiaBlood and lymphatic system disorders7/357
Atrial fibrillationCardiac disorders7/357
Chest painGeneral disorders7/357
Most frequent other events
Showing 10 of 39
Most frequent other events
EventTadalafil 20 mg or 40 mg Double-Blind and 40 mg Open-Label
HeadacheNervous system disorders107/357
DiarrhoeaGastrointestinal disorders77/357
NasopharyngitisInfections and infestations64/357
Back painMusculoskeletal and connective tissue disorders64/357
Oedema peripheralGeneral disorders63/357
Upper respiratory tract infectionInfections and infestations63/357
DizzinessNervous system disorders61/357
DyspnoeaRespiratory, thoracic and mediastinal disorders55/357
CoughRespiratory, thoracic and mediastinal disorders54/357
PalpitationsCardiac disorders52/357

Baseline characteristics

Age Continuous
Age Continuous(years)Tadalafil 20 Milligrams (mg) Double-BlindTadalafil 40 mg Double-BlindTotal
Mean53.04 ± 15.5853.94 ± 15.3653.78 ± 15.38
Sex: Female, Male
Sex: Female, Male(Participants)Tadalafil 20 Milligrams (mg) Double-BlindTadalafil 40 mg Double-BlindTotal
Female48230278
Male156479
Region of Enrollment
Region of Enrollment(participants)Tadalafil 20 Milligrams (mg) Double-BlindTadalafil 40 mg Double-BlindTotal
Belgium257
Canada43842
France32225
Germany63440
Ireland011
Italy42529
Japan51722
Spain246
United States33139172
United Kingdom4913
Race
Race(participants)Tadalafil 20 Milligrams (mg) Double-BlindTadalafil 40 mg Double-BlindTotal
White48243291
Asian72229
Black or African American52328
American Indian or Alaska Native235
Native Hawaiian or Other Pacific Islander022
American Indian or Alaska Native/White011
Black or African American/Native Hawaiian or Other101
Weight
Weight(kilograms (kg))Tadalafil 20 Milligrams (mg) Double-BlindTadalafil 40 mg Double-BlindTotal
Mean73.92 ± 18.9075.26 ± 19.8075.02 ± 19.63
Ethnicity
Ethnicity(participants)Tadalafil 20 Milligrams (mg) Double-BlindTadalafil 40 mg Double-BlindTotal
Hispanic or Latino43640
Not Hispanic or Latino59258317
Etiology
Etiology(participants)Tadalafil 20 Milligrams (mg) Double-BlindTadalafil 40 mg Double-BlindTotal
Idiopathic37186223
Related to Collagen Vascular Disease166278
Associated with Atrial Septal Defect32629
Related to Anorexigen Use41115
Surgical Repair, of at least 1 Year Duration3912
Current Bosentan Use
Current Bosentan Use(participants)Tadalafil 20 Milligrams (mg) Double-BlindTadalafil 40 mg Double-BlindTotal
Yes37155192
No26139165
08

Study locations

10 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon- Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bend, Oregon 97701, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon- Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Brussels, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon- Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Toronto, Ontario, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon- Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lille, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon- Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Berlin, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon- Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Dublin, Ireland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon- Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bergamo, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon- Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tokyo, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon- Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Barcelona, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon- Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    London, United Kingdom
09

References and documents

Publications

  • Oudiz RJ, Brundage BH, Galie N, Ghofrani HA, Simonneau G, Botros FT, Chan M, Beardsworth A, Barst RJ; PHIRST Study Group. Tadalafil for the treatment of pulmonary arterial hypertension: a double-blind 52-week uncontrolled extension study. J Am Coll Cardiol. 2012 Aug 21;60(8):768-74. doi: 10.1016/j.jacc.2012.05.004. Epub 2012 Jul 18. PubMed 22818063 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2005, a primary completion of Feb 2012 and a completion of Feb 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2013, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2007
First posted
Oct 25, 2007
Start
Dec 2005
Primary completionActual
Feb 2012
CompletionActual
Feb 2012
Results first posted
Feb 18, 2013
Last update
Apr 9, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00549302
Collaborators
ICOS Corporation
Responsible party
Sponsor
First posted
Oct 25, 2007
Start date
Dec 2005
Primary completion
Feb 2012
Completion
Feb 2012
Results posted
Feb 18, 2013
Last update
Apr 9, 2013

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tadalafil

Start the discussion